CAPSIVS: Caprini Score in Venous Surgery: a Prospective Cohort Study

Sponsor
Pirogov Russian National Research Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03041805
Collaborator
(none)
3,000
1
96
31.3

Study Details

Study Description

Brief Summary

The aim of the study is to make a validation of Caprini score in patients undergoing varicose veins surgery, especially endovascular procedures (endovascular laser treatment - EVLT, radiofrequency ablation - RFA, ultrasound-guided foam sclerotherapy - USFS) and to identify patients with elevated risk of postoperative venous thromboembolism (VTE) who will benefit from prophylactic anticoagulation.

Condition or Disease Intervention/Treatment Phase
  • Procedure: EVLT
  • Procedure: RFA
  • Procedure: USFS
  • Procedure: HL/stripping
  • Procedure: Miniphlebectomy
  • Procedure: Sclerotherapy
  • Device: GCS
  • Drug: LMWH

Detailed Description

A prospective cohort study based on the platform of Ongoing Registry of Treatment of Chronic Venous Diseases (NCT03035747). The study will enrol adult patients undergoing any kind of varicose veins surgery with and without any prophylaxis. The patients should be examined for venous thromboembolic complications during 2-4 weeks after the procedure with mandatory duplex ultrasound.

The study will provide following information:
  • the rate of asymptomatic DVT after varicose veins surgery

  • the rate of symptomatic VTE after varicose veins surgery

  • the rate of thermal-induced thrombosis (EHIT) after endovenous thermal ablation

  • the ability of Caprini scores to predict VTE after varicose veins surgery

  • identification of patients with high risk of VTE who will benefit from prophylaxis, especially with anticoagulation

Study Design

Study Type:
Observational
Anticipated Enrollment :
3000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Prospective Cohort Register Study for Validation of Caprini Score in Patients Undergoing Varicose Vein Surgery
Actual Study Start Date :
Jan 1, 2017
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Jan 1, 2025

Outcome Measures

Primary Outcome Measures

  1. any episode of VTE [0-4 weeks after procedure]

    symptomatic or asymptomatic, confirmed by instrumental diagnostics

Secondary Outcome Measures

  1. symptomatic deep vein thrombosis [0-4 weeks after procedure]

    symptomatic deep vein thrombosis confirmed by duplex ultrasound

  2. symptomatic pulmonary embolism [0-4 weeks after procedure]

    symptomatic pulmonary embolism confirmed by perfusion isotope scanning or CT pulmonary angiography

  3. asymtomatic deep vein thrombosis [2-4 weeks after procedure]

    asymptomatic DVT revealed by duplex ultrasound

  4. endovenous thermal-induced thrombosis [0-4 weeks after procedure]

    EHIT revealed by duplex ultrasound

  5. major bleeding [0-4 weeks after procedure]

    Fatal bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in haemoglobin level of 20 g/L or more, or leading to transfusion of two or more units of whole blood or red cells.

  6. clinicaly relevant bleeding [0-4 weeks after procedure]

    any non-major bleeding need for treatment or intervention

  7. death for any reason [0-4 weeks after procedure]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age over 18 years

  • any kind of varicose vein surgery

  • follow up for 4 weeks after the procedure

  • examination for VTE at 2-4 weeks after the procedure, including duplex ultrasound

Exclusion Criteria:
  • lost for follow-up during 4 weeks

Contacts and Locations

Locations

Site City State Country Postal Code
1 Pirogov Russian National Research Medical University Moscow Russian Federation 117997

Sponsors and Collaborators

  • Pirogov Russian National Research Medical University

Investigators

  • Study Chair: Kirill Lobastov, PhD, Pirogov Russian National Research Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kirill Lobastov, Associated Professor, Pirogov Russian National Research Medical University
ClinicalTrials.gov Identifier:
NCT03041805
Other Study ID Numbers:
  • CAPSIVS
First Posted:
Feb 3, 2017
Last Update Posted:
Feb 15, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kirill Lobastov, Associated Professor, Pirogov Russian National Research Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 15, 2022